B of A Securities Reiterates Buy Rating on Taysha Gene Therapies
B of A Securities reaffirms its buy rating on Taysha Gene Therapies with a $10 price target, a 61.03% upside from the current price.
Key Points
- B of A Securities reiterated its buy rating on Taysha Gene Therapies, setting a $10 price target on June 23, 2026.
- B of A Securities's $10 price target implies 61.03% upside from Taysha Gene Therapies, Inc.'s ($TSHA) current $6.21 share price.
- Shares of TSHA traded near $6.53 on Tuesday, with a market cap of about $1.88 billion and a 52-week range of $2.25 to $7.30.
- Insiders purchased shares recently, and several analysts, including Needham and Citizens, also maintain buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B of A Securities has reiterated its buy rating for Taysha Gene Therapies, Inc. (NasdaqGS: TSHA), setting a price target of $10. This update came on June 23, 2026, as part of the firm's ongoing coverage of the biotechnology company.
B of A Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Taysha Gene Therapies
Several other institutional investors have been active in Taysha Gene Therapies. RA Capital Management, L.P. held steady with 23.6 million shares valued at approximately $105.3 million. Goldman Sachs Group Inc. increased its stake significantly, adding 8.7 million shares to total 22.4 million shares worth about $100 million, a 63.4% increase. BlackRock, Inc. trimmed its position slightly by 277,521 shares, ending with 18.4 million shares valued at roughly $82.1 million, a 1.5% decrease. Vestal Point Capital, LP also boosted its holdings by 4.25 million shares, now holding 18 million shares valued at $80.5 million, marking a 30.9% increase.
Taysha Gene Therapies, Inc. Stock Up 7.6%
Shares of Taysha Gene Therapies traded near $6.53 on Tuesday. The company has a market cap of around $1.88 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. With a beta of 1.177, the stock has shown some volatility. It has a 52-week low of $2.25 and a high of $7.30, with a 50-day moving average of $5.96 and a 200-day moving average of $4.88. Taysha Gene Therapies has a strong liquidity position, with a current ratio of 14.04 and a quick ratio of 13.76.
$TSHA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Taysha Gene Therapies, Inc.
Recent insider activity at Taysha Gene Therapies includes multiple purchases on June 1, 2026. John Stalfort III, Alison Long, and Laura Sepp-Lorenzino each bought 42,671 shares, while Phillip Donenberg and others made additional buys. These transactions were not part of a planned trading program.
Analysts Set New Price Targets
On June 23, 2026, B of A Securities maintained its buy rating for Taysha Gene Therapies with a $10 price target. Citizens also maintained a buy rating with an $11 target on the same day. Previously, on June 22, Needham kept its buy rating with a $12 target. The consensus among 13 analysts is a strong buy, with an average target price of $12.23.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc. is a biotechnology company based in Dallas, Texas. It focuses on developing gene therapies for severe diseases of the central nervous system using adeno-associated virus technology. Key products under development include treatments for giant axonal neuropathy, Rett syndrome, and several other rare conditions. Led by CEO Sean P. Nolan, the company collaborates with The University of Texas Southwestern Medical Center.
Bottom Line
B of A Securities' reiterated buy rating and $10 price target reflect continued confidence in Taysha Gene Therapies' potential. Investors watch these ratings closely as the company develops treatments for rare diseases. Keep in mind that analyst ratings and price targets are based on past data and expectations, which may change over time.
Get Taysha Gene Therapies, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TSHA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.